The main focus of our research has been to understand the biological functions of two highly related signaling molecules, myostatin (MSTN, GDF-8) and GDF-11, which we discovered in a screen for new transforming growth factor- family members. We showed that mice lacking MSTN have dramatic increases in skeletal muscle mass throughout the body, and we and others showed that systemic administration of MSTN inhibitors to mice can promote muscle growth, showing that MSTN acts to limit muscle growth postnatally. Hence, there is extensive interest in targeting MSTN to enhance muscle strength and regeneration, and at least 7 biotechnology and pharmaceutical companies are in phase II/III clinical trials testing myostatin inhibitors in a wide range of disease settings. We showed that GDF-11 plays an important role in axial patterning and in kidney development, and other groups subsequently showed that GDF-11 also regulates the development of the nervous system and pancreas. Gdf11 is expressed widely in adult tissues, and recent studies have suggested that GDF-11 may play an important role in aging. Specifically, circulating GDF-11 levels were reported to decrease with age, and administration of GDF-11 protein to aged mice was reported to reverse age-related tissue dysfunction in the heart, skeletal muscle, and nervous system. Some of these findings have since been challenged by a paper reporting that GDF-11 levels increase with aging and that GDF-11 has a detrimental effect on skeletal muscle regeneration. These findings have raised new questions regarding the roles of MSTN and GDF-11 in adult animals as well as the potential strategies for manipulating the activities of these molecules for clinical applications. A major question in this regard is whether the distinct functions of MSTN and GDF-11 reflect the inherent biochemical differences between these highly related molecules or whether their distinct functions simply reflect their differing pattern of expression. The overall goal of this project is to understand the basis for the distinct functios of these molecules. This project is a continuation of our long-standing effort to understand the mechanisms underlying the regulation and signaling of MSTN and GDF-11 and will utilize the many genetic and biochemical tools that we have developed over many years to target the various components of this regulatory network.
The Specific Aims are: to compare the activities of MSTN and GDF-11 in vitro with respect to the roles of known signaling components, including inhibitory binding proteins and receptors; to examine the roles of these binding proteins and receptors in regulating skeletal and cardiac muscle growth and function and skeletal muscle regeneration in vivo; and to carry out gene knock-in experiments in mice in which the MSTN coding sequence is replaced with GDF-11 (and vice versa). The results of these experiments should provide key insights into the mechanistic basis underlying the distinct biological functions that MSTN and GDF-11 carry out in vivo. We believe that these studies will be crucial for developing strategies to exploit the activities of these molecules for therapeutic intervention.

Public Health Relevance

The overall goal of this project is to understand the mechanistic basis for the distinct biological functions of myostatin and GDF-11, which are two highly related signaling molecules belonging to the transforming growth factor- superfamily. There is extensive effort being directed at manipulating the activities of these molecules for clinical applications to enhance muscle growth and function and to combat tissue aging, and we believe that the studies outlined in this proposal will be crucial for developing the most optimal strategies to exploit the activities of these molecules for therapeutic intervention.

National Institute of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Research Project (R01)
Project #
Application #
Study Section
Skeletal Muscle Biology and Exercise Physiology Study Section (SMEP)
Program Officer
Boyce, Amanda T
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
Schools of Medicine
United States
Zip Code
Singh, Rajan; Pervin, Shehla; Lee, Se-Jin et al. (2018) Metabolic profiling of follistatin overexpression: a novel therapeutic strategy for metabolic diseases. Diabetes Metab Syndr Obes 11:65-84
Chung, Hyo Kyun; Ryu, Dongryeol; Kim, Koon Soon et al. (2017) Growth differentiation factor 15 is a myomitokine governing systemic energy homeostasis. J Cell Biol 216:149-165
Bondulich, Marie K; Jolinon, Nelly; Osborne, Georgina F et al. (2017) Myostatin inhibition prevents skeletal muscle pathophysiology in Huntington's disease mice. Sci Rep 7:14275
Goh, Brian C; Singhal, Vandana; Herrera, Angelica J et al. (2017) Activin receptor type 2A (ACVR2A) functions directly in osteoblasts as a negative regulator of bone mass. J Biol Chem 292:13809-13822
Khalil, Hadi; Kanisicak, Onur; Prasad, Vikram et al. (2017) Fibroblast-specific TGF-?-Smad2/3 signaling underlies cardiac fibrosis. J Clin Invest 127:3770-3783
Singh, Rajan; Braga, Melissa; Reddy, Srinivasa T et al. (2017) Follistatin Targets Distinct Pathways To Promote Brown Adipocyte Characteristics in Brown and White Adipose Tissues. Endocrinology 158:1217-1230
Eleftheriou, Nikolas M; Sjölund, Jonas; Bocci, Matteo et al. (2016) Compound genetically engineered mouse models of cancer reveal dual targeting of ALK1 and endoglin as a synergistic opportunity to impinge on angiogenic TGF-? signaling. Oncotarget 7:84314-84325
Muir, Alison M; Massoudi, Dawiyat; Nguyen, Ngon et al. (2016) BMP1-like proteinases are essential to the structure and wound healing of skin. Matrix Biol 56:114-131
Park, Benjamin V; Freeman, Zachary T; Ghasemzadeh, Ali et al. (2016) TGF?1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer. Cancer Discov 6:1366-1381
Lee, Yun-Sil; Huynh, Thanh V; Lee, Se-Jin (2016) Paracrine and endocrine modes of myostatin action. J Appl Physiol (1985) 120:592-8

Showing the most recent 10 out of 29 publications